The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is a network for providers that collects longitudinal diagnostic and therapeutic clinical data, including cognitive and functional assessments. ALZ-NET will offer better insight into the long-term health outcomes for patients who receive new FDA-approved Alzheimer's drugs and therapies.
Access to this real-world data will allow clinicians and other health care providers to improve diagnosis and patient care. Meanwhile, researchers will be able to advance the science behind future Alzheimer's and dementia treatments.
Through the ALZ-NET provider care network, health practitioners can sign up to become a participating site. Patients and caregivers can search for clinicians and sites that participate in the network.
Visit the ALZ-NET Provider Network
A word from Maria C. Carrillo, Ph.D., Chief Science Officer, Alzheimer's Association
"We are entering a new phase of Alzheimer's treatment. ALZ-NET is the tool that will help us translate therapies into care that provides the most benefit to people living with the disease and their caregivers, in all communities. In collaboration with partners and scientific leaders, we are looking to develop the future of treatment and diagnostics by collecting data in real-world settings."
Objectives of the Alzheimer's Network for Treatment and Diagnostics
ALZ-NET aims to monitor and report clinical and safety endpoints for patients treated with FDA-approved Alzheimer's therapies, including accompanying diagnostics, to track the long-term outcomes associated with these therapies. Objectives include:
- Develop a multi-site network for patient enrollment and data collection.
- Collect baseline and longitudinal participant data, including measures of cognition and function and information about adverse events.
- Track health outcomes and resource utilization via claims data.
- Collect and archive diagnostic and safety neuroimaging studies, as well as genetic and fluid biomarker data and biosamples.
- Broadly share de-identified data with the research community and other stakeholders.
How to get involved in ALZ-NET
Patients who have been prescribed a novel FDA-approved therapy for Alzheimer’s disease should work with their treating physician to enroll in ALZ-NET. This is a provider enrolled network. Clinicians and specialists who participate in ALZ-NET will register their patients' experiences with new FDA-approved Alzheimer’s disease therapies, including safety and effectiveness. View the ALZ-NET Protocol Synopsis (PDF).
To start the process of becoming a participating site, please fill out the ALZ-NET Site Feasibility and Registration Form. It takes about 10 minutes to complete and asks for information about your site's patient population, imaging facility and staffing.
Begin Site Registration
For questions about timing and participation, or other inquiries about ALZ-NET, please contact email@example.com.